Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.
Squifflet P, Saad ED, Loibl S, van Mackelenbergh MT, Untch M, Rastogi P, Gianni L, Schneeweiss A, Conte P, Piccart M, Bonnefoi H, Jackisch C, Nekljudova V, Tang G, Valagussa P, Neate C, Gelber R, Poncet C, Heinzmann D, Denkert C, Geyer CE Jr, Cortes J, Guarneri V, de Azambuja E, Cameron D, Ismael G, Wolmark N, Cortazar P, Buyse M; CTNeoBC Project. Squifflet P, et al. Among authors: poncet c. J Clin Oncol. 2023 Jun 1;41(16):2988-2997. doi: 10.1200/JCO.22.02363. Epub 2023 Mar 28. J Clin Oncol. 2023. PMID: 36977286
Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes.
Bonnefoi H, MacGrogan G, Poncet C, Iggo R, Pommeret F, Grellety T, Larsimont D, Bécette V, Kerdraon O, Bibeau F, Ghnassia JP, Picquenot JM, Thomas J, Tille JC, Slaets L, Bodmer A, Bergh J, Cameron D; EORTC 10994/BIG 1-00 study investigators. Bonnefoi H, et al. Among authors: poncet c. Br J Cancer. 2019 Apr;120(9):913-921. doi: 10.1038/s41416-019-0420-y. Epub 2019 Mar 22. Br J Cancer. 2019. PMID: 30899086 Free PMC article. Clinical Trial.
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
Delaloge S, Piccart M, Rutgers E, Litière S, van 't Veer LJ, van den Berkmortel F, Brain E, Dudek-Peric A, Gil-Gil M, Gomez P, Hilbers FS, Khalil Z, Knox S, Kuemmel S, Kunz G, Lesur A, Pierga JY, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Thompson AM, Viale G, Zoppoli G, Vuylsteke P, Tryfonidis K, Poncet C, Bogaerts J, Cardoso F; MINDACT investigators and the TRANSBIG Consortium. Delaloge S, et al. Among authors: poncet c. J Clin Oncol. 2020 Apr 10;38(11):1186-1197. doi: 10.1200/JCO.19.01371. Epub 2020 Feb 21. J Clin Oncol. 2020. PMID: 32083990 Free PMC article. Clinical Trial.
Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial.
Retèl VP, Byng D, Linn SC, Jóźwiak K, Koffijberg H, Rutgers EJ, Cardoso F, Piccart MJ, Poncet C, Van't Veer LJ, van Harten WH. Retèl VP, et al. Among authors: poncet c. Eur J Cancer. 2020 Sep;137:193-203. doi: 10.1016/j.ejca.2020.07.002. Epub 2020 Aug 11. Eur J Cancer. 2020. PMID: 32795875 Free article. Clinical Trial.
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Piccart M, van 't Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY, Vuylsteke P, Brain E, Vrijaldenhoven S, Neijenhuis PA, Causeret S, Smilde TJ, Viale G, Glas AM, Delorenzi M, Sotiriou C, Rubio IT, Kümmel S, Zoppoli G, Thompson AM, Matos E, Zaman K, Hilbers F, Fumagalli D, Ravdin P, Knox S, Tryfonidis K, Peric A, Meulemans B, Bogaerts J, Cardoso F, Rutgers EJT. Piccart M, et al. Among authors: poncet c. Lancet Oncol. 2021 Apr;22(4):476-488. doi: 10.1016/S1470-2045(21)00007-3. Epub 2021 Mar 12. Lancet Oncol. 2021. PMID: 33721561 Clinical Trial.
Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.
Lopes Cardozo JMN, Drukker CA, Rutgers EJT, Schmidt MK, Glas AM, Witteveen A, Cardoso F, Piccart M, Esserman LJ, Poncet C, van 't Veer LJ. Lopes Cardozo JMN, et al. Among authors: poncet c. J Clin Oncol. 2022 Apr 20;40(12):1335-1345. doi: 10.1200/JCO.21.02019. Epub 2022 Jan 21. J Clin Oncol. 2022. PMID: 35061525
161 results